Obstructive lung disease: Difference between revisions

Jump to navigation Jump to search
Line 86: Line 86:
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Clinical manifestations
! colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Clinical manifestations
! colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis
! colspan="11" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis
|-
|-
! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms
! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms
! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs
! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |PFT
! colspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |PFT
! colspan="3" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging
! colspan="3" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard
Line 110: Line 110:
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |TLC
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |TLC
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |DLCO
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |DLCO
! rowspan="2" |Flow-Volume loop
|-
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" |CXR
! style="background:#4479BA; color: #FFFFFF;" align="center" |CXR
Line 116: Line 117:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Asthma
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Asthma
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + (night-time)
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
Line 142: Line 143:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*Normal/↑
*Normal/↑
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
* Pulmonary hyperinflation
* Pulmonary hyperinflation
Line 157: Line 159:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Chronic bronchitis
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Chronic bronchitis
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + (greater than equal to 3 months/year for greater than equal to 2 years)
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + (intermittent)
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 172: Line 174:
*Rales
*Rales
*↓Bronchial breath sounds.(present in consolidation)
*↓Bronchial breath sounds.(present in consolidation)
*Hyperresonance


| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑Procalcitonin
*↑Procalcitonin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Normal
*↓[[PaO2]]
*↑[[PaCO2]]
*↓[[pH]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓FEV1
*↓FEV1
Line 183: Line 188:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Normal
*Normal
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Thickening of the bronchial walls in the lower lobes
* Thickening of the bronchial walls in the lower lobes
Line 194: Line 200:
*Chest radiograph
*Chest radiograph
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Secondary to URTI
*Secondary to chronic smoking
*Blue-bloaters
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiolitis
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiolitis
Line 218: Line 225:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓
*↓
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Bronchovascular markings
*Bronchovascular markings
Line 230: Line 238:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Can be associated with:
Can be associated with:
*Organ transplantation
*[[Organ transplantation]] ([[bronchiolitis obliterans]])
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Emphysema
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Emphysema
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" | + (mild cough)
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" | + (severe, constant)
| style="padding: 5px 5px; background: #F5F5F5;" |–
| style="padding: 5px 5px; background: #F5F5F5;" |–
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
Line 245: Line 253:
* Expiratory wheeze
* Expiratory wheeze
* Hyperinflation
* Hyperinflation
* Hyperresonance
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓alpha-1 antitrypsin deficency
*↓alpha-1 antitrypsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Respiratory alkalosis
*↓[[PaO2]]
*Metabolic acidosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓FEV1  
*↓FEV1  
Line 255: Line 263:
*↑
*↑
| style="padding: 5px 5px; background: #F5F5F5;" |–
| style="padding: 5px 5px; background: #F5F5F5;" |–
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Flattening of the diaphragm  
* Flattening of the diaphragm  
Line 266: Line 275:
*Pulse oximetry
*Pulse oximetry
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Physical Exam
* Physical exam
* Spirometery
* Spirometery
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Barrel Chest
* [[Barrel chest|Barrel Chest]]
* [[Hepatitis]]
* [[Fibromuscular dysplasia]]
* [[Pancreatitis]]
* Pink puffers
* Secondary to chronic smoking (centrilobular emphysema)
* Secondary to [[Alpha 1-antitrypsin deficiency|alpha- 1 antitrypsin deficiency]] (panacinar emphysema)
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiectasis 
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiectasis 
Line 294: Line 309:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓
*↓
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Tram track opacities
*Tram track opacities
Line 334: Line 350:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Normal
*Normal
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Bat wing appearance
* Bat wing appearance
Line 351: Line 368:
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Tuberculosis
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Tuberculosis
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" | + (chronic)
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki>
Line 360: Line 377:
| style="padding: 5px 5px; background: #F5F5F5;" |–
| style="padding: 5px 5px; background: #F5F5F5;" |–
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Diminished breath sounds
* Diminished [[breath sounds]]
* Rhonci/wheeze
* [[Rhonchi]]/[[wheeze]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* ↑[[C-reactive protein]]
* ↑[[C-reactive protein]]
* [[Normocytic anemia]]
* [[Normocytic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑
*↑
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Upper lobe infiltrate
* Upper lobe infiltrate
Line 398: Line 417:
| style="padding: 5px 5px; background: #F5F5F5;" | +
| style="padding: 5px 5px; background: #F5F5F5;" | +
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Wheeze
*[[Wheeze]]
*Hyperinflation
*Hyperinflation
*Absent or ↓Breath sounds
*Absent or ↓[[breath sounds]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑Vascular endothelial growth factor-D
*↑[[Vascular endothelial growth factor]]-D
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Respiratory acidosis in severe disease
*[[Respiratory acidosis]] in severe disease
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓FEV1:FVC
*↓FEV1:FVC
Line 411: Line 430:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓DLCO
*↓DLCO
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Ground glass appearance
*Ground glass appearance
*Interstetial pulmonary edema
*Interstetial [[pulmonary edema]]
*Septal thickening
*Septal thickening
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Pulmonary cyst
*[[Pulmonary cystic lymphangiectasis|Pulmonary cyst]]
*Pnuemothorax
*[[Pneumothorax|Pnuemothorax]]
*Pleural masses
*[[Pleural]] masses
*Pleural thickening
*[[Pleural]] thickening
*Mediastianl lymphadenopathy
*[[Mediastinal]] [[lymphadenopathy]]
*Pleural effusion
*[[Pleural effusion]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*VQ Scan
*VQ scan
*PET Scan
*[[PET scan]]
*Advanced lymphatic imaging
*Advanced lymphatic imaging
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 448: Line 468:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑TLC
*↑TLC
*↑Glucose
*↑[[Glucose]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑PCO2
*↑[[PaCO2]]
*↓PO2
*↓[[PaO2]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓FEV1:FVC
*↓FEV1:FVC
Line 459: Line 479:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑DLCO
*↑DLCO
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Pulmonary hyperinflation
*Pulmonary hyperinflation
Line 481: Line 502:
| style="padding: 5px 5px; background: #F5F5F5;" | -
| style="padding: 5px 5px; background: #F5F5F5;" | -
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Crackles
*[[Crackles]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Sweat Chloride test: >60 mEq/L
*[[Sweat chloride test|Sweat chloride tes]]<nowiki/>t: >60 mEq/L
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↑PCO2
*↑[[PaCO2]]
*↓PO2
*↓[[PaO2]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓FEV1:FVC
*↓FEV1:FVC
Line 493: Line 514:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*↓ In severe lung impairment<ref name="pmid12814143">{{cite journal |vauthors=Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME |title=The diffusing capacity in adult cystic fibrosis |journal=Respir Med |volume=97 |issue=6 |pages=606–11 |date=June 2003 |pmid=12814143 |doi= |url=}}</ref>
*↓ In severe lung impairment<ref name="pmid12814143">{{cite journal |vauthors=Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME |title=The diffusing capacity in adult cystic fibrosis |journal=Respir Med |volume=97 |issue=6 |pages=606–11 |date=June 2003 |pmid=12814143 |doi= |url=}}</ref>
|
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |

Revision as of 04:08, 19 March 2018


Obstructive lung disease Microchapters

Overview

Classification

Asthma
COPD
Bronchiolitis
Bronchiectasis
Heart failure
Tuberculosis
Lymphangioleiomyomatosis
Cystic fibrosis

Spirometry Findings in Various Lung Conditions

Approach to Lung Disorders

Differentiating Obstructive Lung Disease from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2], Feham Tariq, MD [3], Dildar Hussain, MBBS [4]

Overview

An obstructive lung disease is a group of diseases characterized by various deformities that result in the collapse of airways. Patients suffering from obstructive lung disease usually present with shortness of breath due to damage to the airways within the lungs. This results in an inability to exhale air completely and an abnormally high amount of air may still present in the lungs after the end of full expiration. One of the main etiology of the obstructive lung disease is long-term exposure to substances that irritate and damage the lung epithelium and lung parenchyma.This includes cigarette smoke, air pollution, chemical fumes, or dust etc. Patients are usually asymptotic during the initial phase of the disease, symptoms usually become more evident as the disease process gets worse. The symptoms usually include a productive cough, difficulty in breathing, wheezing, and tightness in the chest.These diseases include asthma, COPD, bronchiolitis, bronchiectasis, heart failure, tuberculosis, cystic fibrosis, and lymphangioleiomyomatosis. Obstructive lung diseases present with an obstructive pattern that is an increase in total lung capacity (TLC), increase in respiratory volume (RV), a decrease in forced vital capacity (FVC), a decreased forced expiratory volume (FEV1), and a decreased FEV1/FVC, on pulmonary function tests.

Classification

Various diseases that present with an obstructive pattern on pulmonary function tests include:

Spirometry Findings in Various Lung Conditions

Spirometry can help distinguish obstructive lung disease from restrictive lung disease. On spirometry the findings include:[1][2]

Pulmonary Function Test Obstructive Lung Disease Restrictive Lung Disease
Spirometry showing Obstructive and Restrictive Lung Disease ([Source:By CNX OpenStax [CC BY 4.0 (http://creativecommons.org/licenses/by/4.0)], via Wikimedia Commons])
TLC
RV
FVC
FEV1 ↓↓
FEV1/FVC N to
MVV

Approach to Lung Disorders

 
 
 
 
 
 
 
 
 
 
 
 
 
Spirometry
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low FEV1/FVC ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal to high FEV1/FVC ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obstructive Lung Disease
 
 
 
 
 
 
 
 
 
 
 
 
 
Restrictive Lung Disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bronchodilator therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
DLCO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increased FEV1
 
 
 
 
 
 
 
No change in FEV1
 
 
 
Normal DLCO
 
 
 
 
 
 
 
Decreased DLCO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asthma
 
 
 
 
 
 
 
COPD
 
 
 
Chest wall disorders
 
 
 
 
 
 
 
Interstitial Lung Disease
 
 

Differentiating Obstructive Lung Disease from other Diseases

Various diseases presenting with obstructive pattern on pulmonary function tests can be differentiated from each other as follows:

Diseases Clinical manifestations Diagnosis
Symptoms Signs Lab findings PFT Imaging Gold standard Other features
Cough Dyspnea Hemoptysis Fever Weight loss Cyanosis Clubbing JVD Peripheral edema Auscultation ABGs FEV1/FVC TLC DLCO Flow-Volume loop
CXR CT scan Other tests
Asthma + (night-time) + ± ±
  • Wheeze
  • Rhonci
  • ↑IgE
  • Normal
  • ↓FEV1

FEV1:FVC

=<0.7

  • Normal/↑
  • Pulmonary hyperinflation
  • Extensive air trapping[3]
  • Bronchoprovocation testing
  • Peak expiratory flow measurement
  • Physical Exam
  • Spirometery
Associated with:
  • Allergic rhinitis
  • GERD and obesity can mimic asthma
Chronic bronchitis + (greater than equal to 3 months/year for greater than equal to 2 years) + (intermittent) ± +
  • Wheeze
  • Rhonci
  • Egophony
  • Rales
  • ↓Bronchial breath sounds.(present in consolidation)
  • Hyperresonance
  • ↑Procalcitonin
  • ↓FEV1
  • Normal
  • Thickening of the bronchial walls in the lower lobes
  • Thickening of the bronchial walls in the lower lobes[4]
Microbiological testing is done in cases of:
  • Influenza
  • Pertusis
  • Clinical diagnosis
  • Chest radiograph
  • Secondary to chronic smoking
  • Blue-bloaters
Bronchiolitis + + +
  • Wheeze
  • Crackles
  • Normal
  • Bronchovascular markings
  • Air trapping
  • Bronchial wall thickening
  • Bronchoscopy
  • Lung biopsy
  • Thoracoscopic lung biopsy

Can be associated with:

Emphysema + (mild cough) + (severe, constant) + + + +
  • Expiratory wheeze
  • Hyperinflation
  • Hyperresonance
  • ↓alpha-1 antitrypsin
  • ↓FEV1
  • Flattening of the diaphragm
  • Vertical heart
  • Small subpleural collections of gas
  • Centriacinar emphysema
  • Panacinar emphysema
  • Paraseptal emphysema
  • Pulse oximetry
  • Physical exam
  • Spirometery
Bronchiectasis  + + + + + +
  • Rhonci
  • Wheeze
  • Crackles
  • ↑Neutrophils
  • ↓FEV1:FVC
  • Tram track opacities
  • Signet-ring sign
  • Airway dilation
  • Flexible bronchoscopy
  • Chronic productive cough
Heart failure + + + + +
  • S3 gallop
  • Wheeze
  • Rales
  • Respiratory alkalosis
  • Normal
  • Normal
  • MRI
  • Cardiac catheterization
  • Exercise testing
  • Ambulatory ECG monitoring
Tuberculosis + + (chronic) + + +
  • Upper lobe infiltrate
  • Upper lobe cavitation
  • Hilar adenopathy
  • Solitary nodules
  • Pleural effusion
  • Mediastinal lymphadenopathy
  • Fibrotic leisons
  • Distortion of the lung parenchyma
  • Centrilobular 2 to 4 mm nodules
  • Branching linear lesions
  • Patchy small lower lobe infiltrates
Lymphangioleiomyomatosis + + +(<5%) - - - +(rare) - +
  • ↓FEV1:FVC
  • Normal
  • ↓DLCO
  • VQ scan
  • PET scan
  • Advanced lymphatic imaging
  • Surgical lung biopsy
  • Chylothorax(most common lymphatic manifestation)
  • Chyloperitonium
  • Renalangiomyolipoma
Status Asthmaticus + + - ± - - - + -
  • Wheeze
  • Absent or ↓Breath sounds
  • ↓FEV1:FVC
  • < 30% of predictive value
  • ↑TLC
  • ↑DLCO
  • Pulmonary hyperinflation
  • Atypical presentation
-
  • Peak expiratory flow<50% of baseline
  • Clinical diagnosis
  • Pulses paradoxus
Cystic fibrosis + + + + - + + - -
  • ↓FEV1:FVC
  • ↑TLC
  • ↓ In severe lung impairment[5]

References

  1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J (November 2005). "Interpretative strategies for lung function tests". Eur. Respir. J. 26 (5): 948–68. doi:10.1183/09031936.05.00035205. PMID 16264058.
  2. Mehrparvar AH, Sakhvidi MJ, Mostaghaci M, Davari MH, Hashemi SH, Zare Z (2014). "Spirometry values for detecting a restrictive pattern in occupational health settings". Tanaffos. 13 (2): 27–34. PMC 4260070. PMID 25506373.
  3. Gaeta M, Minutoli F, Girbino G, Murabito A, Benedetto C, Contiguglia R, Ruggeri P, Privitera S (2013). "Expiratory CT scan in patients with normal inspiratory CT scan: a finding of obliterative bronchiolitis and other causes of bronchiolar obstruction". Multidiscip Respir Med. 8 (1): 44. doi:10.1186/2049-6958-8-44. PMC 3710098. PMID 23835554.
  4. Park JE, Kim Y, Lee SW, Shim SS, Lee JK, Lee JH (2016). "The usefulness of low-dose CT scan in elderly patients with suspected acute lower respiratory infection in the emergency room". Br J Radiol. 89 (1060): 20150654. doi:10.1259/bjr.20150654. PMC 4846199. PMID 26861744.
  5. Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME (June 2003). "The diffusing capacity in adult cystic fibrosis". Respir Med. 97 (6): 606–11. PMID 12814143.